International audience
-
January 1, 2020 (v1)Journal articleUploaded on: October 14, 2023
-
January 1, 2021 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
September 2021 (v1)Journal article
Background: Docetaxel (DOCE) is a standard of care in metastatic castration-resistant prostate cancer (mCRPC). Several retrospective studies suggested a decrease in Prostate Cancer incidence and mortality with metformin (MET). MET has also demonstrated anti-tumor activity in Prostate Cancer preclinical models, with increased apoptosis when...
Uploaded on: December 4, 2022 -
September 17, 2021 (v1)Journal article
Background: Docetaxel (DOCE) is a standard of care in metastatic castration-resistant prostate cancer (mCRPC). Several retrospective studies suggested a decrease in Prostate Cancer incidence and mortality with metformin (MET). MET has also demonstrated anti-tumor activity in Prostate Cancer preclinical models, with increased apoptosis when...
Uploaded on: December 4, 2022